Logo image of BMA.OL

BYGGMA ASA (BMA.OL) Stock Fundamental Analysis

OSL:BMA - Euronext Oslo - NO0003087603 - Common Stock - Currency: NOK

18  -0.5 (-2.7%)

Fundamental Rating

1

Overall BMA gets a fundamental rating of 1 out of 10. We evaluated BMA against 20 industry peers in the Building Products industry. BMA has a bad profitability rating. Also its financial health evaluation is rather negative. BMA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year BMA has reported negative net income.
BMA had a positive operating cash flow in the past year.
BMA had positive earnings in 4 of the past 5 years.
In the past 5 years BMA always reported a positive cash flow from operatings.
BMA.OL Yearly Net Income VS EBIT VS OCF VS FCFBMA.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

1.2 Ratios

BMA's Return On Assets of -1.97% is on the low side compared to the rest of the industry. BMA is outperformed by 85.00% of its industry peers.
BMA has a worse Return On Equity (-6.12%) than 80.00% of its industry peers.
BMA has a worse Return On Invested Capital (2.25%) than 80.00% of its industry peers.
Industry RankSector Rank
ROA -1.97%
ROE -6.12%
ROIC 2.25%
ROA(3y)2.06%
ROA(5y)4.25%
ROE(3y)5.65%
ROE(5y)11.19%
ROIC(3y)N/A
ROIC(5y)N/A
BMA.OL Yearly ROA, ROE, ROICBMA.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

1.3 Margins

With a Operating Margin value of 2.90%, BMA is not doing good in the industry: 80.00% of the companies in the same industry are doing better.
BMA has a better Gross Margin (50.09%) than 65.00% of its industry peers.
In the last couple of years the Gross Margin of BMA has remained more or less at the same level.
Industry RankSector Rank
OM 2.9%
PM (TTM) N/A
GM 50.09%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.39%
GM growth 5Y-0.63%
BMA.OL Yearly Profit, Operating, Gross MarginsBMA.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40

More info and screens

0

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BMA is destroying value.
The number of shares outstanding for BMA remains at a similar level compared to 1 year ago.
BMA has more shares outstanding than it did 5 years ago.
BMA has a worse debt/assets ratio than last year.
BMA.OL Yearly Shares OutstandingBMA.OL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
BMA.OL Yearly Total Debt VS Total AssetsBMA.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

BMA has an Altman-Z score of 1.51. This is a bad value and indicates that BMA is not financially healthy and even has some risk of bankruptcy.
BMA has a worse Altman-Z score (1.51) than 70.00% of its industry peers.
A Debt/Equity ratio of 1.19 is on the high side and indicates that BMA has dependencies on debt financing.
The Debt to Equity ratio of BMA (1.19) is worse than 80.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.19
Debt/FCF N/A
Altman-Z 1.51
ROIC/WACC0.26
WACC8.73%
BMA.OL Yearly LT Debt VS Equity VS FCFBMA.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M 1B

2.3 Liquidity

BMA has a Current Ratio of 0.78. This is a bad value and indicates that BMA is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of BMA (0.78) is worse than 90.00% of its industry peers.
BMA has a Quick Ratio of 0.78. This is a bad value and indicates that BMA is not financially healthy enough and could expect problems in meeting its short term obligations.
BMA's Quick ratio of 0.44 is on the low side compared to the rest of the industry. BMA is outperformed by 85.00% of its industry peers.
Industry RankSector Rank
Current Ratio 0.78
Quick Ratio 0.44
BMA.OL Yearly Current Assets VS Current LiabilitesBMA.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

1

3. Growth

3.1 Past

BMA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 29.50%, which is quite impressive.
Looking at the last year, BMA shows a small growth in Revenue. The Revenue has grown by 6.30% in the last year.
BMA shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 3.98% yearly.
EPS 1Y (TTM)29.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%191.48%
Revenue 1Y (TTM)6.3%
Revenue growth 3Y-2.58%
Revenue growth 5Y3.98%
Sales Q2Q%17.43%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BMA.OL Yearly Revenue VS EstimatesBMA.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BMA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BMA.OL Price Earnings VS Forward Price EarningsBMA.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, BMA is valued a bit more expensive than the industry average as 75.00% of the companies are valued more cheaply.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 15.48
BMA.OL Per share dataBMA.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BMA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BYGGMA ASA

OSL:BMA (8/8/2025, 7:00:00 PM)

18

-0.5 (-2.7%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryBuilding Products
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners2.7%
Ins Owner ChangeN/A
Market Cap1.26B
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.56
P/FCF N/A
P/OCF 24.25
P/B 1.28
P/tB 1.3
EV/EBITDA 15.48
EPS(TTM)-0.84
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)0.74
OCFY4.12%
SpS32.39
BVpS14.04
TBVpS13.79
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.97%
ROE -6.12%
ROCE 3.37%
ROIC 2.25%
ROICexc 2.28%
ROICexgc 2.3%
OM 2.9%
PM (TTM) N/A
GM 50.09%
FCFM N/A
ROA(3y)2.06%
ROA(5y)4.25%
ROE(3y)5.65%
ROE(5y)11.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.39%
GM growth 5Y-0.63%
F-Score6
Asset Turnover0.74
Health
Industry RankSector Rank
Debt/Equity 1.19
Debt/FCF N/A
Debt/EBITDA 7.61
Cap/Depr 60.63%
Cap/Sales 2.35%
Interest Coverage 0.62
Cash Conversion 33.77%
Profit Quality N/A
Current Ratio 0.78
Quick Ratio 0.44
Altman-Z 1.51
F-Score6
WACC8.73%
ROIC/WACC0.26
Cap/Depr(3y)82.97%
Cap/Depr(5y)85.75%
Cap/Sales(3y)3.16%
Cap/Sales(5y)3.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)29.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%191.48%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)6.3%
Revenue growth 3Y-2.58%
Revenue growth 5Y3.98%
Sales Q2Q%17.43%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y142.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-101.01%
FCF growth 3Y-35.16%
FCF growth 5YN/A
OCF growth 1Y-80.63%
OCF growth 3Y-28.69%
OCF growth 5Y-8.56%